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 Macrophages are versatile players in the immune sys-
tem. They effectively neutralize pathogens and harmful 
endogenous products via phagocytosis but also contrib-
ute to efficient immunity by production and secretion of 
multiple cytokines and chemokines. Next to effector 
functions, macrophages possess important activities dur-
ing the resolution phase of an immune response and at 
sites where antigenic material needs to be ignored (lung 
and colon) or tolerated (eye, brain, ovary, and testis). The 
different macrophage activities result from the initiation 
of distinct gene expression programs  [1–5] . IFN  and 
TNF induce classical activation of macrophages. These 
macrophages, also known as M1 cells, produce high 
amounts of pro-inflammatory cytokines, nitric oxide, 
and reactive oxygen species and efficiently clear patho-
gens either directly or by facilitating T H 1 immune re-
sponses. In contrast, stimulation with IL-4 or IL-13 trig-
gers pathways that program macrophages to exert anti-
inflammatory functions. These alternatively activated 
macrophages, also known as M2a cells, are considered to 
be involved in T H 2 immune responses and wound heal-
ing. Finally, IL-10 and glucocorticoids give rise to regula-
tory macrophages that can inhibit immune responses, 
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 Abstract 
 Classical macrophage activation is inhibited by the CD200 
receptor (CD200R). Here, we show that CD200R expression 
was specifically induced on human in vitro polarized macro-
phages of the alternatively activated M2a subtype, gener-
ated by incubation with IL-4 or IL-13. In mice, peritoneal M2 
macrophages, elicited during infection with the parasites 
 Taenia crassiceps or  Trypanosoma brucei brucei , expressed in-
creased CD200R levels compared to those derived from un-
infected mice. However, in vitro  stimulation of mouse peri-
toneal macrophages and  T. crassiceps infection in IL-4–/– and 
IL-4R–/– mice showed that, in contrast to humans, induction 
of CD200R in mice was not IL-4 or IL-13 dependent. Our data 
identify CD200R as a suitable marker for alternatively acti-
vated macrophages in humans and corroborate observa-
tions of distinct species- and/or site-specific mechanisms 
regulating macrophage polarization in mouse and man. 
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the so-called M2c cells. Although macrophage activation 
generates a wide spectrum of subpopulations with over-
lapping activities, it is useful to identify functionally di-
vergent cells since growing evidence demonstrates that 
these are involved in various pathologies  [4, 5] . Most of 
the current knowledge about surface markers on activat-
ed macrophages is derived from murine models, but data 
from human studies are scarce. Based on functional as-
pects, we reasoned that immune-inhibitory receptors 
such as the membrane glycoprotein CD200 receptor 
(CD200R) might be associated with M2 cells. CD200R, 
mainly expressed on myeloid cells and on a subset of T 
and B cells  [6–8] , inhibits inflammatory macrophage ac-
tivation as illustrated by studies showing that absence of 
its ligand CD200 aggravates, accelerates, or increases the 
susceptibility of inflammatory models, such as experi-
mental autoimmune encephalomyelitis, uveoretinitis, 
and collagen-induced arthritis  [7, 9] . Indeed, CD200R 
signaling profoundly inhibits the MAP kinases p38, ERK, 
and JNK, the common signaling pathways involved in 
classical activation of macrophages  [10] . As M2 cells can 
mediate a T H 2 immune response by producing and se-
creting anti-inflammatory mediators and reducing in-
flammatory cytokines like TNF, it is interesting that 
some of these effects have also been reported for CD200R 
 [11] . However, the expression pattern of CD200R or other 
immune-inhibitory molecules on polarized macrophages 
has never been studied thoroughly.
 To determine the expression of CD200R on polarized 
macrophages, we subjected human monocytes directly 
after purification from peripheral blood to a panel of pro- 
and anti-inflammatory stimuli for 3 days, as described 
previously  [12] , to initiate either M1 activation (IFN  , IL-
1  , and TNF) or M2 activation (IL-4, IL-13, and IL-10; all 
PeproTech, London, UK, or dexamethasone; Sigma Al-
drich, Zwijndrecht, The Netherlands;  fig. 1 ). Additional 
pro- and anti-inflammatory cells, corresponding to M1/
M2 macrophages, were created by culturing monocytes 
in the presence of GM-CSF and M-CSF, respectively 
(both PeproTech)  [13] . Analysis of CD200R mRNA ex-
pression in these cells, performed by quantitative real-
time PCR (qPCR)  [14] , revealed a significant induction 
after stimulation with IL-4 or IL-13 ( fig. 1 ). At protein 
level, determined by flow cytometry using Alexa 674-
labeled anti-human CD200R (Serotec, Oxford, UK), 
CD200R expression was robustly increased by IL-4 stim-
ulation, modestly increased by IL-13, and slightly but not 
significantly following IL-10 and the glucocorticoid dexa-
methasone ( fig. 1 ). These results indicate that CD200R is 
specifically upregulated on alternatively activated M2a 
macrophages, which are at present most commonly iden-
tified by expression of the mannose receptor (MR, CD206) 
 [1] . We therefore compared the expression pattern of 
CD200R with that of MR mRNA by qPCR and protein by 
flow cytometry, using APC-labeled anti-MR (BD Biosci-
ences, San Jose, Calif., USA), in the same series of exper-
iments. MR was indeed induced by IL-4 and IL-13, but 
also by the M1 activator GM-CSF, confirming previously 
reported data  [15] , and to some extent by IL-1  , although 
the latter was not significant ( fig. 1 ). Different from M2a 
cells are M2c cells that are induced by IL-10 and gluco-
corticoids, and are characterized by expression of the 
scavenger receptor CD163  [3] . As expected, CD163 mRNA 
and protein (PE-labeled anti-CD163, BD Biosciences) was 
induced only by IL-10 and dexamethasone and not by IL-
4 or IL-13 ( fig. 1 ), confirming the M2c specificity of this 
marker. To further validate our findings, we cultured 
freshly isolated monocytes for an extended period of 7 
days, the last 3 days being in the presence of either IL-4 
or IL-10. Compared to cells that were cultured for 3 days 
( fig. 1 ), this procedure induced a further increase in 
CD200R mRNA expression following IL-4 stimulation 
(fold induction 14.2  8 2.6, n = 8). Similar to CD200R, the 
increase in MR expression was also much stronger (fold 
induction 14.4  8 2.1, n = 8) while CD163 induction by 
IL-10 was not further upregulated compared to the 3-day 
cultured cells. As expected, CD200R and MR expression 
was not upregulated by IL-10 nor was CD163 induced by 
 Fig. 1. Expression of CD200R by human macrophages maturated 
for 3 days under polarizing conditions. Human primary mono-
cytes were isolated from PBMCs and differentiated into M1 mac-
rophages by stimulation with IFN  (50 ng/ml), IL-1  (40 ng/ml), 
TNF (50 ng/ml), or GM-CSF (50 ng/ml) or into M2 macrophages 
by stimulation with M-CSF (25 ng/ml), IL-4 (40 ng/ml), IL-13 (50 
ng/ml), IL-10 (50 ng/ml), or dexamethasone (Dex; 2 n M ). After
72 h, mRNA and protein expression of CD200R, MR, CD163, and 
TREM2 were determined by qPCR and flow cytometry, respec-
tively. Transcript data ( a ) are depicted as mean fold induction  8 
SEM compared to macrophages cultured in medium only [num-
ber of donors (n) = 3; 2 independent experiments]. Protein data 
( b ) are depicted as mean fluorescence intensity (GEO mean )  8 
SEM (CD200R, n = 11; MR, n = 5; CD163, n = 6; TREM2, n = 3; 
2–6 independent experiments). Representative histograms ( c ) 
show protein expression levels of cells cultured with IL-4 (bold 
line), IL-10 (thin line), or medium alone (grey), with geometric 
means indicated by the corresponding numbers (isotype controls 
left and antibodies right).  * 0.01  ! p  ^  0.05;  * * 0.001  !  p  ^  0.01; 
 * * * p  ! 0.001 (one-way ANOVA and post-hoc Dunnett’s multiple 
comparison test).  
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IL-4 (data not shown). Thus, whereas CD163 is an excel-
lent marker for M2c cells, CD200R is abundantly ex-
pressed on human M2a cells, with even higher specificity 
than MR, and appears to be a novel reliable marker for 
this type of macrophage in vitro.
 We next tested whether two other inhibitory mole-
cules expressed on myeloid cells, TREM2 and SIRP   [16–
18] , are also primarily expressed by alternatively activat-
ed macrophages. A significant induction of TREM2 was 
found after IL-13 stimulation at mRNA level, but not
at protein level (biotinylated anti-TREM2, PeproTech; 
 fig. 1 ). IL-4 did not induce TREM2 expression. Expres-
sion of SIRP  , determined at the mRNA level, was not 
induced by any of the investigated stimuli (data not 
shown), indicating that induction of immune-inhibitory 
molecules is not a common phenotype of experimentally 
polarized human M2 macrophages, and seems restricted 
to CD200R.
 Because CD200R is present on various leukocytes  [19] , 
we compared its expression levels on in vitro polarized 
macrophages with that on primary myeloid cells.  Table 1 
shows that CD200R is most abundant on basophilic gran-
ulocytes, which is in agreement with previous studies 
 [20] . CD200R expression on monocytes, myeloid den-
dritic cells, and splenic macrophages was lower compared 
to M2a cells generated in vitro.
 Experimental infection of mice with parasites is known 
to provoke strong type 2 immune responses correlating 
with an M2 signature of the elicited macrophages  [21] . To 
test whether CD200R is expressed on M2 cells in vivo, we 
analyzed peritoneal macrophages isolated from animals 
infected with either the helminth  Taenia crassiceps or the 
protozoan  Trypanosoma brucei brucei , inoculated as de-
scribed previously  [21] . Indeed, macrophages from  T. 
crassiceps -infected mice (C57BL/6 and BALB/c) showed 
increased CD200R mRNA expression compared to those 
derived from uninfected mice ( fig. 2 a). Mice infected 
with phospholipase C-deficient (PLC–/–)  T. b. brucei dis-
play a switch from a type 1 cytokine milieu during the 
early stage of the infection to a type 2 environment in the 
chronic phase of the disease  [21] . CD200R expression was 
unaltered or even slightly decreased on peritoneal mac-
rophages derived from the acute phase, but robustly up-
regulated on macrophages derived from the chronic 
phase ( fig. 2 a). In both parasite models, regulation of 
CD200R expression correlated well with the established 
mouse M2 markers arginase-1 (Arg-1) and ‘found in in-
flammatory zone 1’ (FIZZ1)  [21] (online suppl. table S1, 
www.karger.com/doi/10.1159/000252803). These results 
indicate that CD200R is also induced on mouse M2 mac-
rophages  in vivo.
 We next determined whether CD200R expression on 
mouse M2 macrophages was induced by IL-4 or IL-13, as 
shown in our previous studies in human macrophages. 
Surprisingly, IL-4 (R & D Systems, Minneapolis, Minn., 
USA) and IL-13 (Sanquin, Amsterdam, The Netherlands) 
failed to induce CD200R mRNA expression in resident 
peritoneal macrophages from C57BL/6 mice after 24 
(data not shown) and 48 h in vitro ( fig. 2 b), whereas in-
duction of alternatively activated macrophages was con-
firmed by upregulation of Arg-1 and FIZZ1 (online suppl. 
table S1). IL-21 was recently reported to augment alterna-
tive macrophage activation  [22] . In line with these data, 
we found that IL-21 (Sanquin) alone did not induce Arg-
1 or FIZZ1, but enhanced the expression of these markers 
when added to IL-4 plus IL-13 (online suppl. table S1). 
After stimulation with this potent combination of cyto-
kines, again, no upregulation of CD200R was detected 
( fig. 2 b). Stimulation with IL-10 (PeproTech) had no ef-
fect on CD200R expression ( fig. 2 b) and IFN  (Pepro-
Tech) seemed to decrease CD200R expression levels. 
Also, in thioglycolate-elicited peritoneal macrophages 
from either C57BL/6 (T H 1-prone) or BALB/c (T H 2-prone) 
mice, IL-4 or IL-10 did not affect CD200R expression 
(online suppl. table S1). In vivo, we confirmed that the 
elevated CD200R expression in M2 cells was indeed IL-4 
Table 1. Protein expression levels of CD200R on human myeloid 
cells
Cell type (n) Fold difference of geometric
MFI over control Ig 
(mean8SEM)
Macrophages
Monocyte-derived macrophages
Polarized with IL-4 (11)
Non-polarized (11)
Splenic macrophages (3)
49.689.6
11.682.5
10.181.4
Monocytes
CD16– monocytes (5)
CD16+ monocytes (5)
20.282.2
10.680.8
Dendritic cells
BDCA1+ myeloid DC (4)
BDCA4+ plasmacytoid DC (4)
12.481.3
1.380.1
Granulocytes
Basophils (4)
Neutrophils (5)
Eosinophils (5)
90.989.1
24.585.2
12.581.1
MFI = Mean fluorescence intensity; n = number of donors.
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independent as no abrogation of CD200R induction was 
observed in IL-4–/– or IL-4R–/– mice infected with  T. 
crassiceps  ( fig. 2 c). The exact conditions causing CD200R 
induction in the mouse are currently unknown, but may 
involve site-specific combinations of cytokines including 
also inflammatory signals  [23] . Interestingly, M2a mark-
ers expressed in the dermal environment in the mouse 
also appear to be independent of IL-4  [24] .
 In summary, we here demonstrate that the immune-
inhibitory molecule CD200R is induced on human mac-
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 Fig. 2. CD200R expression in mouse alternatively activated mac-
rophages  in vivo  and in vitro.  a Transcription of CD200R was 
determined by qPCR in peritoneal macrophages isolated from 
C57BL/6 mice 4 weeks after infection with  T. crassiceps (left pan-
el) and from BALB/c mice 6, 22, and 31 days after infection (mid-
dle panel). CD200R expression was also determined in peritoneal 
macrophages isolated from C57BL/6  ! BALB/c (F1) mice in the 
early (2 weeks) and chronic (3–4 months) stage of infection with 
PLC–/–  T. b. brucei  (right panel; n = 2–3 mice per group).  b Induc-
tion in CD200R mRNA in resident peritoneal macrophages iso-
lated from C57BL/6 mice stimulated with IFN  , IL-4, IL-13, IL-21, 
IL-10 (all 50 ng/ml), or combinations thereof for 48 h (n = 3 ex-
periments, cells are pooled from 4–5 mice per experiment).
 c Induction of CD200R mRNA on peritoneal macrophages iso-
lated from BALB/c wild-type, IL-4–/–, and IL-4R–/– mice infect-
ed with  T. crassiceps . Data are depicted as mean fold induction  8 
SEM compared to macrophages from non-infected mice ( a ), un-
treated cultures ( b ), and non-infected wild-type (WT) mice ( c ;
n = 3). * 0.01  ! p  ^  0.05;  * * * p  ! 0.001 (one-way ANOVA and post 
hoc Dunnett’s multiple comparison test).  
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rophages polarized in vitro following IL-4 or IL-13 stim-
ulation and can be used as a novel cell surface marker for 
M2a cells in human. Furthermore, CD200R is also ex-
pressed on mouse M2 cells, but in contrast to humans, is 
not induced by classical type 2 cytokines in vitro. CD200R 
ligation induces immune suppression and will thus con-
tribute to the immune-regulatory capacity of M2 macro-
phages. By repressing pathways associated with classical 
macrophage activation  [10] , CD200R may also be associ-
ated with maintaining M2 cells in their polarized state, 
which enables them to create a milieu that favors T H 2 im-
mune responses, and tissue homeostasis and repair. Lack 
of this regulatory pathway, for instance in CD200–/– 
mice, could then lead to exacerbation of (auto)immune 
diseases as reported previously  [4, 7, 9, 23] . 
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